A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab [clinicaltrials:NCT00001805]
A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab [clinicaltrials:NCT00001805]
Bio2RDF identifier
NCT00001805
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00001805
identifiers.org URI
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
This is a phase II clin ...... and anti-tumor
effects.
brief title [clinicaltrials_vocabulary:brief-title]
A Phase II Clinical Trial of S ...... Immunotoxin LMB-1 by Rituximab
completion date [clinicaltrials_vocabulary:completion-date]
2000-06-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
This is a phase II clin ...... and anti-tumor
effects.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
1999-11-03T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
keyword [clinicaltrials_vocabulary:keyword]
Breast Cancer
Colon Cancer
Gastric Cancer
Lung Cancer
Pancreatic Cancer
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2008-03-03T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00001805
official title [clinicaltrials_vocabulary:official-title]
A Phase II Clinical Trial of S ...... Immunotoxin LMB-1 by Rituximab
org study id [clinicaltrials_vocabulary:org-study-id]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
reference [clinicaltrials_vocabulary:reference]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1999-03-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2000-03-01T00:00:00Z
identifier
clinicaltrials:NCT00001805
title
A Phase II Clinical Trial of S ...... Immunotoxin LMB-1 by Rituximab
@en
type
label
A Phase II Clinical Trial of S ...... b [clinicaltrials:NCT00001805]
@en